ProCE Banner Activity

Treatment Considerations for Stenotrophomonas maltophilia Infections

Clinical Thought

Stenotrophomonas maltophilia has been increasingly implicated in healthcare-acquired infections and intrinsically resistant to commonly used broad-spectrum β-lactam agents (eg, piperacillin/tazobactam, cefepime, carbapenems). Read this case study to learn my approach to S. maltophilia infections, including considerations for combination therapy.

Released: February 22, 2023

Expiration: February 21, 2024

No longer available for credit.

Share

Faculty

Yohei Doi

Yohei Doi, MD, PhD

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh School of Medicine
Infectious Diseases Specialist
Division of Infectious Diseases
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Shionogi Inc

Disclosure

Yohei Doi, MD, PhD: consultant/advisor/speaker: bioMérieux, Chugai, Fujifilm, Gilead Sciences, GlaxoSmithKline, Meiji Seika Pharma, Moderna, MSD, Shinogi; researcher: Entasis.